NCT04274036

Brief Summary

Stigmatization is especially studied in mental disorders such as schizophrenia. In recent years, different chronic diseases such as AIDS, tuberculosis, and diabetes have also been shown to decrease in quality of life due to the "stigma" of these patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
108

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 13, 2020

Completed
Same day until next milestone

Study Start

First participant enrolled

February 13, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

February 18, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2020

Completed
Last Updated

February 18, 2020

Status Verified

February 1, 2020

Enrollment Period

4 months

First QC Date

February 13, 2020

Last Update Submit

February 16, 2020

Conditions

Keywords

FibromyalgiaSocial SupportStigma

Outcome Measures

Primary Outcomes (5)

  • Visual Analog Scale

    A scale to measure pain which "0" shows no pain and "10" shows worst pain ever

    Baseline

  • Discomfort Intolerance Scale

    The Discomfort Intolerance Scale is brief, self-report index of the degree to which individuals tolerate physical discomfort including pain. Items for this scale were developed by experts in pain and anxiety. Participants rate the questions on a scale ranging from 0 (not at all like me) to 6 (extremely like me). Higher points show worst outcomes.

    Baseline

  • The Distress Tolerance Scale

    Distress tolerance is defined as the capacity to experience and withstand negative psychological states. Distress may be the result of cognitive or physical processes but manifests in an emotional state often characterized by action tendencies to alleviate the emotional experience. Distress tolerance is considered a meta-emotion construct that consists of one's evaluations and expectations of experiencing negative emotional states in respect to tolerability and aversiveness, appraisal and acceptability, tendency to absorb attention and disrupt functioning, and regulation of emotions, specifically, the consequent strength of action tendencies to either avoid or immediately attenuate the experience

    Baseline

  • Fibromyalgia Impact Questionnaire - Revised

    The revised Fibromyalgia Impact Questionnaire has 21 individual questions All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst'.

    Baseline

  • Stigma Scale for Chronic Illness

    The stigma scale consists of 24 items. Item scores range from 1 (never) to 5 (always). A summary index is calculated by adding all scores, ranging from 24 to 120, with higher scores reflecting the worst stigmatization.

    Baseline

Study Arms (2)

Fibromyalgia Patients

Fibromyalgia patients diagnosed according to the 2016 American College of Rheumatology criteria.

Healthy-Controls

Healthy controls without pain or chronic illness

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Fibromiyalgia patients and healthy controls with an allocation ratio of 2:1.

You may qualify if:

  • Patients over the age of 18
  • To be diagnosed with fibromyalgia according to American College of Rheumatology 2016 revised criteria

You may not qualify if:

  • Have been diagnosed and treated with fibromyalgia before
  • Presence of any diagnosis that can cause secondary fibromyalgia (rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis)
  • The presence of anemia
  • Vitamin D deficiency
  • Presence of known endocrine, neurological and cardiac diseases
  • Antidepressant use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gaziosmanpasa Taksim Research and Education Hospital

Istanbul, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

FibromyalgiaSocial Stigma

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesSocial BehaviorBehavior

Central Study Contacts

Mehmet Akif Guler, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 13, 2020

First Posted

February 18, 2020

Study Start

February 13, 2020

Primary Completion

May 31, 2020

Study Completion

May 31, 2020

Last Updated

February 18, 2020

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations